...
首页> 外文期刊>Hepatology research: the official journal of the Japan Society of Hepatology >Cutaneous sarcoidosis in a chronic hepatitis C patient receiving pegylated interferon and ribavirin therapy
【24h】

Cutaneous sarcoidosis in a chronic hepatitis C patient receiving pegylated interferon and ribavirin therapy

机译:接受聚乙二醇干扰素和利巴韦林治疗的慢性丙型肝炎患者的皮肤结节病

获取原文
获取原文并翻译 | 示例
           

摘要

A 61-year-old Japanese woman suffered from a small, painful, subcutaneous nodule on the sole of her foot that was 10mm across in diameter during pegylated interferon (PEG IFN) and ribavirin (RBV) combination therapy for chronic hepatitis C. Skin biopsy revealed multiple non-caseating granulomas composed of epithelioid histiocytes with multinucleate giant cells, which was consistent with sarcoidosis. Ophthalmologic examination revealed uveitis. Thoracic computed tomography (CT) showed multiple bilateral hilar lymphadenopathies and a diffuse micronodular interstitial pattern of the lungs. Genetic analysis indicated a probable homozygous haplotype of A*02:01-C*15:02-B*51:01-DRB1*16:02-DQB1*05:02 in human leukocyte antigen regions. The patient was observed carefully without any additional medication because no significant systemic symptoms were noted. Combination therapy was continued for 2months afterwards. She was asymptomatic for over 3years of follow up, and repeated hematological and biological investigations and chest CT showed improvement. In conclusion, clinicians should bear sarcoidosis in mind as a complication during PEG IFN and RBV combination therapy. They should also be aware of the usually good prognosis of PEG IFN-induced cutaneous sarcoidosis in order not to prematurely discontinue a treatment necessary for liver disease; maintenance of PEG IFN treatment may be advised with careful follow up.
机译:一名61岁的日本妇女在聚乙二醇干扰素(PEG IFN)和利巴韦林(RBV)联合治疗慢性丙型肝炎期间,脚底皮下有一个小的疼痛结节,直径为10mm。揭示多发非干酪样肉芽肿,由上皮样组织细胞和多核巨细胞组成,与结节病一致。眼科检查发现葡萄膜炎。胸廓计算机断层扫描(CT)显示出多发性双侧肺门淋巴腺病和肺部弥漫性微结节样病变。遗传分析表明在人白细胞抗原区域中A * 02:01-C * 15:02-B * 51:01-DRB1 * 16:02-DQB1 * 05:02可能是纯合单倍型。由于没有发现明显的全身症状,因此在没有任何其他药物的情况下仔细观察了患者。此后继续联合治疗2个月。经过3年多的随访,她无症状,反复进行血液和生物学检查,胸部CT表现良好。总之,在PEG IFN和RBV联合治疗期间,临床医生应牢记结节病作为并发症。他们还应意识到PEG IFN诱导的皮肤结节病通常预后良好,以免过早停止治疗肝病所需的治疗;建议维持PEG IFN治疗并仔细随访。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号